Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.

摘要: The acquired immune response that leads to graft rejection depends on regulated adhesive interactions between T lymphocytes, endothelial cells, dendritic tissue and the extracellular matrix coordinate cellular trafficking activation of antigen-reactive lymphocytes. Inhibiting function molecules involved in adhesion processes offers potential for interfering with allograft response. leukocyte associated antigen-1 molecule (LFA-1), a heterodimer CD11a (alphaL) CD18 (beta2) integrin subunits, is an attractive therapeutic target because it plays important role key steps inflammation rejection. These include: (1) binding leukocytes endothelium; (2) through activated (3) costimulatory lymphocytes antigen presenting cells. Clinical experience efalizumab, humanized anti-CD11a monoclonal antibody (mAb), patients chronic plaque psoriasis has shown therapy well tolerated effective at reducing severity disease without depleting Initial results renal transplant are also promising.